Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1999

View Archived Issues

Immtech's treatment for parasitic infections to enter phase I clinical trials

Hybridon presents HYB-165, the first orally active antitumor oligonucleotide

Chiron licenses HCV patent rights to Abbott

Cell Pathways and RPR to study Aptosyn in combination with Taxotere

Gliatech commences product development program for schizophrenia and dementia

ImmunoGen exercises put option

Licensing opportunity from NIH: globotriaosylceramide as a promoter of HIV-1 entry into cells

Northwest Biotherapeutics and Battelle form prostate cancer collaboration

NPS Pharmaceuticals and Allelix to merge

Atrix reports postmarketing study results for Atridox periodontitis therapy

York Medical to commence phase I/II trial of head and neck cancer therapy

Long-term efficacy and tolerability reported for MTX-HSA in preliminary clinical testing

Molecumetics and P&U enter collaboration for caspase research

XTL Biopharmaceuticals' human MAb enters phase I HBV trials

NeoTherapeutics initiates second phase IIb clinical trial of Neotrofin

Banyu identifies potent, selective muscarinic M3 antagonist series

Hydroxamic acid-based inhibitors of TNF-alpha production under study at Yoshitomi

Antiallergic agents described by Senju in recently issued patent

Phospholipase inhibitors synthesized and tested at Genetics Institute

New antitumor compounds from Schering-Plough act by inhibiting protein farnesyltransferase

Texas A&M describes important new class of agents for breast cancer

Novel class of quinoline-indoles: discovery, activity and pharmacokinetics discussed at ICAAC

DHFR inhibitors designed by Roche for activity against resistant Gram-positive bacteria

Levosimendan improves symptoms and prolongs survival in patients with various types of HF

News from ICAAC: characterization of water-soluble prodrug of the azole antifungal Sch-56592

Samjin's SJ-3366: a promising anti-HIV compound with a dual mechanism of action

Oral ETA antagonist ABT-627 shows signs of efficacy, safety in CHF

Detailed activity profile, predicted human pharmacokinetics of E-1010 presented at ICAAC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...